

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
Email: \_\_\_\_\_  
DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_ Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
Tax I.D.: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY:**

ICD-10: \_\_\_\_\_  Acute  Chronic

Date of Diagnosis: \_\_\_\_\_ Contraindications:  No  Yes \_\_\_\_\_

**Diagnosis Procedure(s) or Laboratory Test(s):**

Test/Procedure:	Date Performed:	Results:
1. _____	_____	_____
2. _____	_____	_____
3. _____	_____	_____

**Prior Failed Treatments:**

**Length of Treatment:**

_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

**If Prior Authorization is Denied:**

Automatically Draft Appeal for Review  Send Preferred Formulary Alternatives

**4 INJECTION TRAINING:**  Pharmacist to Provide Training  Patient Trained in MD Office  Manufacturer Nurse Support

**5 PRODUCT DELIVERY:**  MD Authorize Delivery to Patient's Home  Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:**

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_ **Must Provide All Prescription Information**

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> ABILIFY MAINTENA®	<input type="checkbox"/> 300mg Lyophilized Powder <input type="checkbox"/> 400mg Lyophilized Powder	<input type="checkbox"/> _____		
<input type="checkbox"/> ARISTADA®	<input type="checkbox"/> 441mg Prefilled Syringe <input type="checkbox"/> 662mg Prefilled Syringe <input type="checkbox"/> 882mg Prefilled Syringe	<input type="checkbox"/> _____		
<input type="checkbox"/> EVZIO®	<input type="checkbox"/> 2mg/0.4ml Autoinjector	<input type="checkbox"/> _____		
<input type="checkbox"/> INVEGA SUSTENNA®	<input type="checkbox"/> 39mg Prefilled Syringe <input type="checkbox"/> 78mg Prefilled Syringe <input type="checkbox"/> 117mg Prefilled Syringe <input type="checkbox"/> 156mg Prefilled Syringe <input type="checkbox"/> 234mg Prefilled Syringe	<input type="checkbox"/> _____		
<input type="checkbox"/> RISPERDAL CONSTA®	<input type="checkbox"/> 12.5mg Vial/Kit <input type="checkbox"/> 25mg Vial/Kit <input type="checkbox"/> 37.5mg Vial/Kit <input type="checkbox"/> 50mg Vial/Kit	<input type="checkbox"/> _____		
<input type="checkbox"/> VIVITROL®	<input type="checkbox"/> 380mg Vial/Kit	<input type="checkbox"/> _____	1	11
<input type="checkbox"/> ZYPREXA® RELPREVV™	<input type="checkbox"/> 210mg Vial <input type="checkbox"/> 300mg Vial <input type="checkbox"/> 405mg Vial	<input type="checkbox"/> _____		
<input type="checkbox"/> _____	_____	_____		

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.